News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
AstraZeneca PLC’s U.S. Sales Tumble As Generics Bite
October 28, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Bloomberg -- AstraZeneca Plc, the U.K.’s second- biggest drugmaker, fell the most in almost nine months in London trading after saying fourth-quarter comparisons would be “demanding” as generic competition cuts into profit.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
AstraZeneca
MORE ON THIS TOPIC
Layoff Tracker
Biogen axes ‘small number’ of Apellis roles after $5.6B buy
June 26, 2026
·
63 min read
·
BioSpace Editorial Staff
Pipeline
Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms
June 26, 2026
·
2 min read
·
Tristan Manalac
M&A
Merck KGaA inks $11B Bio-Techne buyout to expand into cell therapy production
June 26, 2026
·
2 min read
·
Nick Paul Taylor
Insights
The Golden Triangle and the gaps: Rethinking UK biotech
June 25, 2026
·
1 min read
·
Jennifer C. Smith-Parker